Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Low-Dose immunotherapy boost chemo for hodgkin lymphoma?

NCT ID NCT06984146

Recruiting now Disease control Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding a flat, low dose of the immunotherapy drug nivolumab to standard chemotherapy (AVD) can improve outcomes for adults with newly diagnosed advanced classic Hodgkin lymphoma. The study will enroll 54 participants and track how long they live without the cancer progressing, overall survival, and side effects. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (immunotherapy) plus doxorubicin, vinblastine, and dacarbazine (chemotherapy)
What this could lead to
If successful, this could offer a more effective first-line treatment for advanced Hodgkin lymphoma, potentially improving long-term remission rates.
What could go wrong
This is a small, early-phase trial (54 people) with no control group, so results may not be definitive. Adding immunotherapy to chemo can increase side effects like immune reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA, ADULT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation

    RECRUITING

    Moscow, Russia

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.